Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 20, 2019
Daily News
November 20, 2019
- Japan’s 1st HIF-PH Inhibitor Hits Market, Kyorin Pushes Back Lasvic Launch amid Desalex Resupply
November 20, 2019
- Japan Grants Orphan Status to Tepotinib and More
November 20, 2019
- 70% of Japanese Still Think HIV Is “Deadly Disease”: Gilead Survey
November 20, 2019
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
- 83 ADR Reports from Patients Received in 4 Months after March Launch of New Reporting System: MHLW
November 20, 2019
- Generic Association to Present Policy Proposal for Govt’s 2020 Honebuto Policy
November 20, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…